LAB DOM AVMM (SUISSE) INC

MF III

OF SWITZERLAND

PLACENTA

Placenta in its fresh and purest native form

HP™
230mg / 400mg

PURE
FRESH
BIO-ACTIVE

The world's only placenta by Cold Processed Cryoporosis™ Extraction with proprietary Sterilization Technology which does not involve any INTENSE HEAT as commonly done through pasteurization.

Best known for its general revitalization, tissue and organs regeneration and overall rejuvenation with anti-ageing demonstrated properties

Introduction

Placenta derives from the Latin word meaning "flat cake". In general, placenta is referred to as the 'afterbirth'. The placenta and baby share; until the time of birth, the same uterus, genes and heritage. In most cases, the placenta and its attached membranes emerge after the baby has been born. The midwife or doctor will then examine the placenta to assess its general condition. When the inspection has been done, the placenta is disposed of. How this is done differs from culture to culture and from one individual to the next. In other words, it largely depends on the influence of culture or personal choice.

The placenta, with its huge potential of medical benefits are often overlooked. Most often, the placenta is regarded as clinical waste and quickly bagged and binned. On the other hand, the newborn baby is cuddled and loved. This perhaps could be due to the placenta's unpleasant appearances that it is often "shun" in most cultures.

The placenta contains over 128 rich growth factors (including HGF, NGF, EGF, FGF, CFS, IGF-1, TGF, IL1, IL2, IL3, and IL4), hormones, proteins, glycosaminoglycans, nucleic acids, polydeoxyribonucleotides (PDRN), antibodies, and other concentrated nutrients that can rejuvenate organic tissues.

The placenta's cytokines mitogenic actions results in an impressive array of physiological effects. Some examples are:

- Youth Restoration & Anti-Ageing
- Regenerates cells, tissues, and organs
- Immunotropic anti-oxidant & anti-inflammatory
- Regulation of autonomous nervous system
- Promotes and maintain healthy circulation of blood
- Ensures comprehensive tissue repair & wound healing
- Enhancement of nerve regeneration
- Balances overall hormonal levels
- Improvement of gastrointestinal transit time which leads to elimination of constipation
- Increases flexibility in joints and discs
- Enhance and strengthen immune system against diseases
- Improves mental alertness and awareness synthesis and re epithelisation, reinforce epidermis hydration which ultimately leads to a firmer, brighter and smoother skin texture
- Improves dermis density by accelerating collagen
- Improves sleep patterns
- Enhances stamina and energy level
- Renews sexual vigour
- Reduce pre-menstrual tension and related feminine problems
- Alleviates pre-menopausal syndrome
- Combat obesity and hence, induce proper weight management
- Decreases serum concentrations of cholesterol and triglycerides
- Decreases risk of arteriosclerosis and atherosclerosis
- Relieves symptoms related to certain chronic diseases

In summary, placenta is a safe therapeutic agent with potent regenerating activities on all human tissue. When introduced into humans internally, it can reinforce deteriorating cells and hence restoring youth and vitality.

Not all Placenta Extracts are the same.

Why **MFIII** Placenta HP is different and produces a much better result?

MFIII Placenta HP products come in sets of 20 or 50 of 2ml vials of highly concentrated 230mg & 400mg pure native placenta extracts. The **MFIII** Placenta HP is the world's only Placenta Extract with its extract, highly bio-active in pure and fresh form. As such, **MFIII** Placenta HP must be kept preferably within + 4°C and + 8°C and not more than 25°C to maintain its efficacy and bio-activeness. This is made possible using our unique microporosis ultra-filtration sterilization and proprietary Cold Process Cryoporosis™ Extraction technology where no heating is ever applied. This is in contrast to other placenta injectables, where sterilization by extreme heating process at +125°C or +180°C are unavoidably adopted. Heat would render almost all the bio-actives in the Placenta destroyed or changed in its molecular structure.

Our UNRIVALLED SAFETY and QUALITY CREDENTIALS



HACCP
Hazard Analysis and Critical Control Points



ISO 9001:2000
Quality Management System



ISO 14001:2004
Environmental Management System

DQS
Quality Management System

IQNet
Management System

EUROPEAN UNION
Certification for Closed Colony of animals (30 generations)

UNIEQUIP
Equipment Quality
Pass : Uniflow S.D.4

SQS
Quality Management System
In development and
Manufacture of tissue culture

LGA
Approved Safety

MILLIPORE
Certificate of Quality

MILLIPORE
Certificate of Compliance

GMP
Good Manufacturing Practice

Safety and Effectiveness Of Our MFIII Placenta

The safety and effectiveness of MFIII Placenta are results of decades of R&D, wealth of experiences and are demonstrated through various number of studies. Procured using Stem Cell Technology, MFIII Placenta is manufactured from our Stem Cells Plant in the European Union, under the most stringent safety and quality assurance regulations.

The number of phagocytic neutrophil cells were higher after 15 days of Placental Therapy treatment than the control.

Marked Antioxidant action. Increases SOD activity & catalase activity by 60%



Increase collagen synthesis, improves tensile strength of the healing tissue remarkably



In grossly infected wounds produces 64% faster healing effect compared to antibiotics.



Increased the size of macrophages significantly.

- *Increased IgG & IgM level by more than 100%*
- *Increased T-cell count significantly on 14th day p<0.01 and highly significant changes visible on 21st day p<0.001.*

Increased the number of phagocytic cells by almost 3 times.

Produced 34.61% increase in neutrophils count by 15th day

Animal Group	Dose of Placental Therapy	Differential Count on 0' day		Differential Count on 15th day		Differential Count on 30th day	
		N*	L*	N	L	N	L
Treated	0.08 ml/20g (I.P.)	57	43	70	30	65	35
Control	----------	56	44	52	48	59	41

Enhances the percentage of mean total protein, DNA, RNA, Hydroxyproline more than conventional therapy

Biochemical Criteria (mg/g)	Placental Therapy Topical	Soframycin Topical	Untreated Control
Total Protein	14.21	13.51	6.2
DNA	1.52	1.16	0.88
RNA	0.5	0.5	0.38
Hydroxyproline	3.51	3.09	0.83

Increases body's defence mechanism significantly increasing WBC count by 62.65% on 15th day

Animal Group	Dose of Placental Therapy	Mean Total WBC Count (cmm) on 0' day	Mean Total WBC Count (cmm) on 15th day	Mean Total WBC Count (cmm) on 30th day
Treated	0.08ml/20g (i.p)	4,768	7,262	7,125
Control	----------	4,525	4,550	4,583

Indications Of Placenta Treatment

The clinical application of MFIII Placenta HP depends on age related diseases and symptoms. Indications of placenta treatment include; but are not limited to fatigue, infertility, frozen shoulder, shoulder stiffness, migraine, joint pain, depression, skin ageing, pre-menstrual syndrome, endometriosis, insomnia, liver dysfunction, fungal infection, digestive problems, nerve related discomfort, coldness of the extremities, anaemia, low libido, constipation and gastritis.
Such treatment attempts to regulate hormones including DHEA, estrogen, progesterone, testosterone, thyroid hormone, growth hormone, melatonin, and cortisol, which are all affected by the ageing process. Placenta, with practically no side effects, can enhance and work synergistically with other modes of anti-ageing therapies.

Placenta extract has also shown to aid in the treatment of Gaucher's disease, strengthen the kidneys and even prevent post natal depression. It has the potential to aid in the treatment and rejuvenation of a number of different conditions as it contains amino acids, vitamins and hundreds of enzymes.

The Accelerated Wound Healing Actions of Placenta Therapy

Non-healing ulcer with pale granulations, punched out edge and the tendons.



Same ulcer as seen 3 weeks after Placental Therapy treatment, showing cherry red granulations and sloping edge.

Biological Effects Of Placenta

The biological effects of placenta for many different conditions have been demonstrated in numerous experiments and studies:

Heals Skin Conditions, Burns and Wounds

Research has shown the positive effect of placenta extract on skin conditions. Bigliardi used a semi-greasy placenta ointment for acute radiodermatitis. With external application of this ointment, he discovered a drastic improvement in subjects' skin condition.

– Ref Note [Shimazaki, J., Yang, H.Y. & Tsubota, K.; Opthamology, 104(12) , 2068-2076 (1997).]

In many countries, intra-muscular and topical use of placental extract for burn injuries, chronic wounds and as post-surgical dressing is an age-old practice. Shimazaki et al. (means 'and others') explored the use of amniotic membrane for patients with chemical and thermal burns. They studied and treated the eyes of patients with severe chemical burns with a transplant of amniotic membrane on the sclera. The amniotic membrane was not rejected in any of the case-studies. Scientists found that visual acuity markedly improved in each eye, and regenerated conjunctiva was stable with mild scarring.

– Ref Note [Ramakrishnan, K.M., Jayaraman, V.; Burns, 23 , S33-S36 (1997).]

Ramakrishnan et al. used amniotic membrane from HbSAg, HIV seronegative mothers as a temporary biological dressing on superficial and deep partial-thickness burns. They noted a reduction in pain, early drying of the wound and epithelialisation.

– Ref Note [Pharmacological Data on Polydeoxyribonucleotide of human placenta,

Bianchini P et al Int. Jr. Tiss. Reac. 111 (3-4) 151-154, 1981.]
Clinical trials with placental extract conducted by Shukla et al. have established healing of chronic, non-healing wounds.

– Ref Note [Corticotropin-Releasing Factor-like Activity in Human Placental Extracts: T Shibasaki et al: Jour. Clinical Endorcrinology & Metabolism 1982, 55(2) 384-396. A joint collaborative study by Japan & USA.]

Maral et al., Datta et al., Pati et al., Muratore et al., Hanada et al., Sato et al. and Subramanyam found similar results in improving healing wounds and other skin conditions.

– Ref Note [Bigliardi, P.; Int. J. Tiss. React., 4 , 153-154 (1982). • Pharmacological Study on Placental Extract: Dr Lalitha Kameswaran Prof. Director, Dept. of Pharmacology Madras Medical College. • Experiments carried out at Indian

Inst. of Chem. Biol. (ICMR) Calcutta 1988 Data on File, ADL. • Institute Research Pharmacol 28, 383-96, 1981. • Multicentric Clinical Studies with Placentrex MF III in Osteoarthritis (Reports submitted for publication) Dr. M.S. Ghosh, Calcutta, Dr. R.S. Dhir, Bombay and Dr. M.F. arook, Madras. • Immunomodulating Potential of certain agents: Placentrex MF III Dept. of Pharmacology, MLN Med. College Allahabad, U.P, India; Report Publd. Jr of Assoc. Phys. India, January 1991. • Effects of Placental Dressing in Indolent Ulcers: T. Subramanian et al: Jr Ind. Med. Assoc. November 1990, 314-316. • Keratinocyte Growth - promoting activity from Human Placenta: E.J. O'Keefe et al: Jr. of Cellular Physiology 124: 439-445: 1985. • Stimulation of Thymidine Incorporation in Keratinocytes by Insulin, Epidermal Growth Factor, and Placental Extract: Comparison with Cell number to assess growth: E.J. O'Keefe et al: Jr Invest. Dermatol 90: 2-7, 1988.]

Placental extract has also been responsible for healing ulcerative lesions of lower limbs.

– Ref Note [Human Placenta for chronic leg ulcers: Goldfab G et al: Lancet, 1980: 11:40.]

Reduces Pain

Oral sub-mucous fibrosis manifests as stiffness of oral mucosa, a burning sensation and an inability to eat. Katharia et al. utilised placenta extract to achieve results. Placenta extract was administered parenterally and effects were monitored in reducing the severity of the disease. There was significant improvement in mouth opening, colour of oral mucosa, burning sensation, and reduction of fibrous bands.

– Ref Note [Placental Extract supports ossification: Arch. Orthop Traum, Surgery, 97, 281-83, 1980.]

Treatment of Gastric or Duodenal Ulcers (BOCD)

The parenteral administration of placenta for the treatment of gastric and duodenal ulcers was investigated in Japan, conducted by Nakazawa et al. Using endoscopic and X-ray technology as diagnostic tools, they found 95% of patients in the group treated with placenta extract were responsive to treatment.

– Ref Note [Dr M.S. Chakraborty Prof. & Head Dept. of Virology, Calcutta School of Tropical Medicine, May 1989 data on File, ADL.]

Bianchini et al. found similar results.

– Ref Note [Shukla, V. K., Rasheed, M. A., Kumar, M., Gupta, S. K. & Pandey, S. S.; Journal of Wound Care, 13 , 177-179 (2004).]

Eases Inflammation (BOCD)

Sur et al. showed the anti-inflammatory effects of human placental extract by inducing inflammation in the hind paws of rats. They found a significant inhibition of paw oedema in the group treated with human placental extract.

– Ref Note [Maral, T., Borman, H., Arslan, B., Demrhani, B., Akinbingol, G., & Haberal, M.; Burns, 25 , 625-635 (1999).]

Defies Malignancy (BOCD)

Using fast growing and undifferentiated rat tumour cells, Carbo et al. demonstrated the inhibitory action of pregnant rat plasma. Tumour cells from untreated rats were seeded in culture dishes with or without the presence of pregnant rat plasma. In comparison with cells that were grown in the presence of virgin rat plasma, there was a 34% decrease in growth in the culture dishes with pregnant rat plasma. Pregnant rat plasma induced apoptosis in tumour cells.

– Ref Note [Datta, P. & Bhattacharyya, D.; J. Pharm. Biomed. Anal., 34 , 1091-1098 (2004).]

Inhibits Bacterial and Fungal Growth

Chakraborty et al. studied the role of placenta on the growth of different bacteria. They found that placenta prevents the growth of clinically isolated bacteria, such as E. coli from urine and blood culture. The found placenta to also have an inhibitory role in the growth of bacteria such as E. coli, Staphylococcus aureus, and fungi such as Saccharomyces cerevisae, Kluyvero-myces fragilis, and Candida albicans.

– Ref Note [Datta, P. & Bhattacharyya, D.; J. Chromatogr. B., 818 , 67-73 (2005).]

Inhibits Viral Growth

The factors controlling HIV-1 transmission from mother to infant are not clearly understood. Studies in the past have suggested the existence of maternal and placental protective mechanisms that inhibit viral replication in utero. Sharma et al. explored the role of placenta on the HIV-1 virus. Their studies demonstrated that a derivative of human placental stromal cells protected HIV-1 infected cells from virus-induced apoptosis and suppressed virus production.

– Ref Note [Datta, P. & Bhattacharyya, D.; J. Pharm. Biomed. Anal., 36 , 211-218 (2004).]

Therapy Recommendation

The Placental Therapy is a standardized treatment for each individual patient who is seeking for general revitalisation. However, for different types of chronic diseases, the selection and dosage depend upon:

- Duration and severity of the disease,
- Age of the patient,
- State of the patient, and
- The observed healing tendency

Individualized dose depends on the severity of the disease, duration of existence and age of the patient. It is crucial for the therapists to gain as much knowledge as possible with regards to the patient's history, as this allows the adoption of a specific, individualized placental therapy against the disease.

The absence or lack of certain information would direct the therapy towards the symptoms instead of the root cause, thereby, the desired therapeutic goal may not be attained.



The indicated dosage can be increased in severe cases. Specific genetic originating diseases should receive regular treatment series repetitions. However in milder cases, a lower quantity can be used.

The goal of Placental Therapy is to have all organs and whole system functioning properly at its optimum level. Nevertheless, these therapy recommendations frequently require fine-tuning. Placental Therapy may be used as a supplement to medication already being used and therefore adjustment of dosage is applicable. This adjustment is to be executed under control of the appropriate parameters and with consideration of advice respective to the manufacturer.

The therapy can be executed in such a way that each second day 2 vials are administered (6 vials/ week). Depending upon the case, the weekly dose can be varied between 4-12 vials over a course of 50 vials. In order to evaluate whether prolonged or subsequent treatment is necessary, an observation time of 10-12 weeks following treatment is fundamental.

The injection is to be administered intramuscularly, subcutaneous into the upper outside quadrant of the gluteus. Opened vials are to be injected immediately, as sterility can be compromised. Clear solutions without any sediments should be used.



MFIII Placenta HP, the obvious choice!

Compare the difference. The Facts speaks for themselves.

FEATURES	MFIII HP	OTHERS
• Origin of Manufactured Product	European Union	Questionable
• Lab & Plant Certifications	Yes	No
• ISO 9001:20001 German Certification	Yes	Mostly None
• ISO 14001 German Certification	Yes	Mostly None
• IQNet Swiss Certification	Yes	Mostly None
• SQS Swiss Quality Management System in development and manufacture of tissue culture Certificate, Switzerland	Yes	Mostly None
• HACCP Certification, Germany	Yes	Mostly None
• Proprietary Cold-Processed CryoporosisTM Extraction	Yes (one of its kind - refrigeration process)	No. All via heating process
• Fresh & Pure Extraction	Yes	No
• No chemical, No preservatives	Yes	No
• Use of Intense heat during pasteurization / sterilization process	Absolutely No	Yes (125°C to180°C)
• Native placental cells used	Yes	No
• Unique Microporosis ultra-filtration sterilization	Yes	No
• GMP Pharmaceutical to European Union stringent standards	Yes	Mostly None
• EU Certification of closed colony (30 generations)	Yes	None
• 'Milipore' USA Certification	Yes	Mostly None
• Support of Swiss Researchers & Cell Therapists worldwide (Switzerland, Germany, Austria, USA, South America and etc).	Yes	None
• Products endorsement by The International Association for Cell Therapy (IACT), Switzerland	Yes	No
• Brand Existence	Yes (18 years)	Mostly 2 - 3 years

If the preferred choice is of animal placenta, they are from certified closed colony of rabbits breed since 1973, with adherence and full guidelines from WHO (World Health Organization) and AAALAC (American Association for Accreditation of Laboratory Animal Care).

Rabbits has proven to be the most suitable animal with Zero Record of Zoonosis transmissions. It is the only animal with no Genus Retroviridae [viruses] classification or taxonomy.

This is further attested in:

1. Murphy F.A., Fauquet C.M., Bishop D.H.L., et al.: Virus Taxonomy (Sixth Report of the International Committee on Taxonomy of Viruses), Springer Verlag, Vienna - New York, 1995, pp 23 - 42, and update of 2000.
2. Fauquet C.M., Pringle C.R.: Abbreviations for vertebrate virus species names. Arch Virology 144, 1999, 1865 – 1880.
3. Murphy A.F., Gibbs E.P.J., Horzinek M.C., Studdent M.J.: Veterinary Virology, Academic Press, San Diego, New York, London, 1999, pp273 - 278.

Manufactured under pharmaceutical GMP conditions in the European Union

Placenta manufacturing and extraction in our Stem Cells Plant in Europe

For more info on **MFIII** of Switzerland other placental products, please go to:

www.mf3-ct.com (for physicians worldwide),
www.mf3.ch (Supplements),
www.vegetal-placenta.com
www.nano-cells.com, and
www.ns-mart.com

Researched, Developed and Licensed by:

Lab Dom AVMM (Suisse) Inc.
(Co No. 676998)
Leutschenbachstrasse 95,
8050 Zurich, Switzerland.
Sales : info@ns-mart.com
Email : info@mf3-ct.com